Which vaccine is NOT administered to an HIV-positive child?

DSSSB - 28 August 2019 (Shift-1)

Child Health Nursing (Pediatrics)

Hard

Appeared in: DSSSB - 28 August 2019 (Shift-1)

Explanation

OPV (Oral Polio Vaccine) is a live attenuated vaccine, meaning it contains a weakened but living poliovirus.
In an immunocompromised child, such as one with HIV, this weakened virus can replicate uncontrollably and cause vaccine-associated paralytic poliomyelitis (VAPP).
Due to this significant risk, OPV is contraindicated in HIV-positive children.
A safe and effective alternative, the Inactivated Polio Vaccine (IPV), which contains a killed virus, is available and recommended for this population.

Option A: Hepatitis B vaccine is a recombinant vaccine, which does not contain live virus. It is considered safe and is recommended for HIV-positive children.
Option B: The DPT vaccine contains diphtheria and tetanus toxoids and whole-cell killed pertussis organisms. As it does not contain any live components, it is safe to administer to HIV-positive children.
Option D: MMR is also a live attenuated vaccine, which makes it a strong distractor. However, it is often administered to HIV-positive children who are not severely immunocompromised (based on CD4 counts). This is because natural measles infection is very severe and often fatal in this group, so the benefit of vaccination outweighs the risk. In contrast, the contraindication for OPV is more absolute due to the availability of the safer IPV alternative.

Clinical Relevance

Nursing practice connection: This is primarily an exam-oriented knowledge point with limited direct bedside application, so retain Immunization guidelines for immunocompromised children, specifically those with HIV infection as background academic context rather than a clinical decision trigger.
A critical nursing responsibility is to screen patients for contraindications before vaccine administration. This includes assessing for immunosuppression due to conditions like HIV, cancer, or immunosuppressive therapy.
Failure to identify an immunocompromised state before giving a live vaccine can lead to severe, life-threatening infections.
What if the question stated the child was born to an HIV-positive mother but the child's own HIV status was indeterminate? In this case, routine vaccinations are typically started, but IPV would be used instead of OPV from the beginning as a precaution.

How to Approach the Question

First, identify the key clinical condition of the patient in the question stem: 'HIV-positive child'. This immediately signals an immunocompromised state.
Next, recall the fundamental principle of vaccination: live attenuated vaccines are generally contraindicated in immunocompromised individuals.
Categorize the vaccines listed in the options as either 'live' or 'inactivated/killed'. Hepatitis B and DPT are inactivated. OPV and MMR are live.
This narrows the choice down to OPV and MMR. Now, you must differentiate between them. Consider if a safer alternative exists for one.
Recall that the Inactivated Polio Vaccine (IPV) is a safe and effective alternative to OPV. This makes the contraindication for OPV much more strict and universal for immunocompromised patients.
While MMR is also live, it's often given cautiously to non-severe HIV cases because the disease itself is so dangerous. Since a safer polio alternative (IPV) exists, OPV is the vaccine most definitively 'NOT administered'.

Concept Tested & Keywords

Concept Tested: Immunization guidelines for immunocompromised children, specifically those with HIV infection.
Stem keywords: vaccine, NOT administered, HIV-positive child
Lead-in keywords: NOT
Clinical cues: Patient condition: HIV-positive child, which implies an immunocompromised state.
Negative lead-in flag: The question asks which vaccine is NOT administered, indicating a contraindication.

QemSD9fYlUhECv2jyZp79A

E6 Ghai Essential Pediatrics(pp 26-904 of 913) p. 215-217

E6 Nelson Textbook of Pediatrics(2024) — Volume 1 p. 1601-1603

E6 Parks TextBook of Preventive & Social Medicine part 1 — Subpart A (pp 26-201 of 604) p. 152-154